NCT03987035已完成不适用
Physician-Initiated Trial Investigating the BeGraft Peripheral Stent Graft System as Bridging Stent in FEVAR for Complex Aortic Aneurysms
Marc Bosiers, MD12 个研究点 分布在 1 个国家目标入组 103 人开始时间: 2021年3月18日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 103
- 试验地点
- 12
- 主要终点
- Efficacy endpoint (2) ) Bridging stent patency at 12 months
研究概览
简要总结
The objective of this clinical investigation is to evaluate, in a controlled setting, the safety and performance of the BeGraft Peripheral (BGP) balloon expandable covered stent Graft System (Bentley InnoMed, Hechingen, Germany) implanted as bridging stent in FEVAR (fenestrated endovascular aortic repair) for complex aortic aneurysms.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 55 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient eligible for elective repair of AAA/TAAA extent IV with FEVAR in accordance with the applicable guidelines for vascular interventions (Aneurysm size 5.5cm or aneurysm growth of >5 mm within 6 months or 1 cm within 1 year).
- •Patient is willing to comply with specified follow-up evaluations at the specified times
- •Patient is >55 years old
- •Patient understands the nature of the procedure and provides written informed consent, prior to enrollment in the study
- •Patient has a projected life-expectancy of at least 12-months
- •Indication of elective repair of AAA or TAAA with FEVAR in accordance with the applicable guidelines for vascular interventions
- •Patient needs to have a landing zone in their target vessel of at least 10mm
- •No early important division branch from the target vessel with risk of coverage
- •Absence of dissection
- •Target vessels (renal arteries, superior mesenteric artery and celiac trunk) should have a diameter between 5 and 10 mm
- •Patient eligible for fenestrated endovascular repair as per IFU of the fenestrated endograft
- •Angulation of the aorta at the level of the target vessels <45 degrees
- •The fenestrated endograft has to be constructed so the fenestrations lie in front of the orifice of the target vessel, and the gap between the fenestration and the orifice of the target vessel should not exceed 10mm.
排除标准
- •Previously implanted endograft
- •Patients refusing treatment
- •Patients for whom antiplatelet therapy, anticoagulants or thrombolytic drugs are contraindicated
- •Patients with uncorrected bleeding disorders or heparin induced thrombozytopenia
- •Female patient with child bearing potential not taking adequate contraceptives or currently breastfeeding
- •Any planned surgical intervention/procedure within 30 days of the study procedure
- •Any patient considered to be hemodynamically unstable at onset of procedure
- •Patient is currently participating in another investigational drug or device study that has not completed the entire follow up period.
- •Patients with diffuse distal disease resulting in poor stent outflow
- •Fresh thrombus formation
- •Stenosed (>50%) or occluded target vessel
- •Angulation between renal artery and aortic wall <30 degrees
- •Patients with known hypersensitivity to the stent material (L605) and/or PTFE
- •Hybrid Approach
- •Patients with a connective tissue disorder
- •Patients with mycotic or inflammatory aneurysm
- •Myocardial infarction or stroke within 3 months prior to the procedure
- •Patients with an unstable angina pectoris or heart insufficiency NYHA 3 or 4
- •Patients with ASA classification 5 or higher
- •Contraindications against contrast enhanced angiography (a.e. massive hyperthyroidism)
- •Patients with increased risk of intraoperative rupture
- •Patients with access vessel which are too tortuous, narrow or any kind of reason that would lead to failure of introducing and advancing an introducer sheath
结局指标
主要结局
Efficacy endpoint (2) ) Bridging stent patency at 12 months
时间窗: 12 months post-op
defined as absence of restenosis (≥50% stenosis) or sole target vessel occlusion based on CT Angio at 12 months
Safety endpoint at 12 months
时间窗: 12 months post-op
Absence of procedure related complications and bridging stent related endoleaks at 12 months
Efficacy endpoint (1) - Technical success
时间窗: 1 day post-op
Successful introduction and deployment of the BeGraft Peripheral (BGP) balloon expandable covered stent Graft System (Bentley Innomed, Hechingen, Germany) implanted as bridging stent in FEVAR
次要结局
- Bridging stent patency post-procedure(1 day post-op, 6-, 12, and 24- months post-op)
- 30-day mortality(30 days post-op)
- Freedom from AAA diameter increase(6-, 12, and 24- months post-op)
- Freedom from aneurysm related secondary endovascular procedures post-procedure(1 day post-op, 6-, 12, and 24- months post-op)
- Freedom from conversion to open surgical repair post-procedure(1 day post-op, 6-, 12, and 24- months post-op)
- Health Related Quality of Life scores(12- and 24-months post-op)
- Freedom from bridging stent related endoleaks post-procedure(1 day post-op, 6-, 12, and 24- months post-op)
- Freedom from stent graft migration post-procedure(1 day post-op, 6-, 12, and 24- months post-op)
- Freedom from bridging stent related secondary intervention post-procedure(1 day post-op, 6-, 12, and 24- months post-op)
- Freedom from type I & III endoleaks post-procedure(1 day post-op, 6-, 12, and 24- months post-op)
- Freedom from aneurysm related mortality post-procedure(1 day post-op, 6-, 12, and 24- months post-op)
- Freedom from aneurysm rupture within 12- and 24-months post-implantation(12, and 24- months post-op)
- Freedom from any major adverse events post-procedure(1 day post-op, 6-, 12, and 24- months post-op)
研究者
Marc Bosiers, MD
Director
FCRE (Foundation for Cardiovascular Research and Education)
研究点 (12)
Loading locations...
相似试验
进行中（未招募）
不适用
BGP+ Stent as Bridging Stent in BEVARThoracoabdominal Aortic Aneurysm, Without Mention of RuptureNCT03982940Marc Bosiers, MD118
已完成
1 期
Study on the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-2004 Injection in Adult Patients With Atrial FibrillationAtrial FibrillationNCT06280768Beijing Suncadia Pharmaceuticals Co., Ltd10
已完成
1 期
Pyrimethamine as a Treatment for Late-Onset GM2-gangliosidosis (Tay-Sachs and Sandhoff Disease)Gangliosidoses, GM2Sandhoff DiseaseTay-Sachs DiseaseNCT01102686The Hospital for Sick Children20
进行中（未招募）
2 期
Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1HIV-1-infectionNCT06532656Gilead Sciences75
招募中
早期 1 期
A Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC PatientsAdvanced Hepatocellular CarcinomaNCT06418659Shanghai Changzheng Hospital37